CC
EPIX

Caxton Corporation’s ESSA Pharma EPIX Stock Holding History

Caxton Corporation’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-26,590
Closed -$183K – 45
2020
Q3 		$183K Buy
+26,590
New +$180K 0.17% 16

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Caxton Corporation's EPIX Position: Q4 2020 in Review

Caxton Corporation sold out of ESSA Pharma (EPIX) in Q4 2020, closing a stake of 26,590 shares — an estimated $183K sold.

Caxton Corporation first reported a position in EPIX in Q3 2020 and held it in 1 quarter. The position peaked at $183K in Q3 2020. 40 funds tracked by Wall St. Rank hold EPIX as of Q4 2020.

  • Caxton Corporation reported no remaining ESSA Pharma position as of Q4 2020 after selling out during the quarter.
  • Caxton Corporation sold 26,590 ESSA Pharma shares in Q4 2020, an estimated $183K.
  • Caxton Corporation first reported a position in ESSA Pharma in Q3 2020 and held it in 1 quarter.
  • Caxton Corporation's ESSA Pharma position peaked at $183K in Q3 2020.
  • 40 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2020.

Based on Caxton Corporation's 13F filing for Q4 2020, filed 16 Feb 2021.